MedPath

VIIV HEALTHCARE PTY LTD

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Lamivudine(LAM) Good Responder Study

Completed
Conditions
Hepatitis B, Chronic
Interventions
Other: No intervention
First Posted Date
2010-05-24
Last Posted Date
2016-09-13
Lead Sponsor
ViiV Healthcare
Target Recruit Count
1
Registration Number
NCT01128686
Locations
🇰🇷

GSK Investigational Site, Kangwon-do, Korea, Republic of

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)

Phase 4
Completed
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Drug: Reyataz + Norvir + Truvada
Drug: Reyataz + Epzicom
First Posted Date
2010-04-13
Last Posted Date
2013-11-19
Lead Sponsor
ViiV Healthcare
Target Recruit Count
297
Registration Number
NCT01102972
Locations
🇵🇷

GSK Investigational Site, San Juan, Puerto Rico

A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects

Phase 1
Completed
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Drug: Raltegravir
Drug: GSK2248761
Drug: GSK2248761 + Raltegravir
First Posted Date
2010-04-12
Last Posted Date
2017-09-11
Lead Sponsor
ViiV Healthcare
Target Recruit Count
15
Registration Number
NCT01101893
Locations
🇺🇸

GSK Investigational Site, Buffalo, New York, United States

GSK1349572 Relative Bioavailability Study

Phase 1
Completed
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Drug: GSK1349572 formulation AP
Drug: GSK1349572 formulation AW
Drug: GSK1349572 formulation AX
First Posted Date
2010-04-02
Last Posted Date
2017-06-09
Lead Sponsor
ViiV Healthcare
Target Recruit Count
24
Registration Number
NCT01098513
Locations
🇺🇸

GSK Investigational Site, Austin, Texas, United States

GSK1349572 Drug Interaction Study With Efavirenz

Phase 1
Completed
Conditions
Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions
Drug: GSK1349572
Drug: Efavirenz
First Posted Date
2010-04-02
Last Posted Date
2017-09-25
Lead Sponsor
ViiV Healthcare
Target Recruit Count
12
Registration Number
NCT01098526
Locations
🇺🇸

GSK Investigational Site, Buffalo, New York, United States

PENTA Fosamprenavir Study

Completed
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Drug: Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)
First Posted Date
2010-03-01
Last Posted Date
2017-06-01
Lead Sponsor
ViiV Healthcare
Target Recruit Count
1
Registration Number
NCT01077635

Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status

Completed
Conditions
Fracture
Infection, Human Immunodeficiency Virus
Interventions
Other: No Antiretroviral (ARV) Drug Exposure
Drug: Any Antiretroviral (ARV) Drug Exposure
First Posted Date
2010-03-01
Last Posted Date
2017-06-01
Lead Sponsor
ViiV Healthcare
Target Recruit Count
1
Registration Number
NCT01077557

Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers

Phase 1
Completed
Conditions
Infection, Human Immunodeficiency Virus
HIV Infections
Interventions
Drug: GSK1349572
First Posted Date
2010-02-15
Last Posted Date
2019-06-24
Lead Sponsor
ViiV Healthcare
Target Recruit Count
18
Registration Number
NCT01068925
Locations
🇺🇸

GSK Investigational Site, Austin, Texas, United States

Effect Of Maraviroc On The Pharmacokinetics Of Digoxin

Phase 1
Completed
Conditions
Healthy
HIV Infections
Interventions
Drug: Digoxin
Drug: Maraviroc
First Posted Date
2010-01-26
Last Posted Date
2011-04-07
Lead Sponsor
ViiV Healthcare
Target Recruit Count
12
Registration Number
NCT01056874
Locations
🇸🇬

Pfizer Investigational Site, Singapore, Singapore

HIV Treatment and CVD Events

Completed
Conditions
HIV Infection
Cardiovascular Disease
Infection, Human Immunodeficiency Virus
Acute Myocardial Infarction
Interventions
Drug: HAART Treatment
First Posted Date
2010-01-22
Last Posted Date
2011-07-27
Lead Sponsor
ViiV Healthcare
Registration Number
NCT01054638
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy